sb 202190 has been researched along with Parkinsonian Disorders in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zawada, WM | 1 |
| Meintzer, MK | 1 |
| Rao, P | 1 |
| Marotti, J | 1 |
| Wang, X | 1 |
| Esplen, JE | 1 |
| Clarkson, ED | 1 |
| Freed, CR | 1 |
| Heidenreich, KA | 1 |
1 other study available for sb 202190 and Parkinsonian Disorders
| Article | Year |
|---|---|
Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Enzyme Inhibitors; | 2001 |